- Lirilumab continues to be well-tolerated in monotherapy and in combination across multiple tumor indications in an exploratory clinical program with partner Bristol-Myers Squibb
- The combination of nivolumab plus lirilumab in an extended population of patients with squamous cell carcinoma of the head and neck (SCCHN) did not provide clear evidence of benefit to patients or an obvious development path –discussions are ongoing regarding next steps
- Full data from the previously disclosed EffiKIR trial to be presented at ASH Annual Meeting 2017 suggests that alternate dosing regimens may have potential for improved patient benefit
- Innate Pharma is pursuing a broad and diversified pipeline of proprietary and partnered programs according to plan and expects to provide an update at an R&D event in early 2018
- Conference call to be held today at 6:30 pm CET
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today provides an update on the clinical study program of lirilumab, licensed to Bristol-Myers Squibb. Lirilumab is a fully human antibody directed against the inhibitory killer-cell immunoglobulin-like receptors (KIRs) expressed predominantly on circulating natural killer (NK) cells.
While lirilumab was shown to be well-tolerated, the assessment of efficacy from the ongoing exploration of doublet combinations, notably the nivolumab combination in an extended population of SCCHN patients, did not provide clear evidence of benefit to patients or an obvious development path.
Discussions are ongoing regarding next steps for the program.
Mondher Mahjoubi, Chief Executive Officer at Innate Pharma, commented: “Clearly this is disappointing, but we remain convinced, based on broad preclinical evidence, that NK cells play an important role in cancer immunosurveillance. Together with Bristol-Myers Squibb, our partner, we will further examine these data to better understand the results and explore whether other combinations should be investigated.”
Separately, full data from the previously disclosed Phase II EffiKIR trial testing lirilumab as a single agent maintenance treatment in elderly patients with acute myeloid leukemia will be discussed at the upcoming ASH Annual Meeting 2017 in an oral presentation on December 11, 6:15pm ET, by the principal investigator Pr. Norbert Vey, Team leader Translational Medicine – Hematology at the Paoli-Calmettes Institute (IPC). These data suggest that alternate dosing regimens, where KIR receptors are not permanently occupied and allow the interaction with their cognate ligands during maturation, could be worth exploring. The presentation will be made available in the lirilumab section of Innate’s website following the event.
Mondher Mahjoubi added: “As opposed to NKG2A receptors, KIRs in addition to controlling anti-tumor activity play a pivotal role in NK cell maturation. Maturation requires the interaction between KIRs and their cognate MHC class I ligands and thus full occupancy of the receptor may lead to dysfunction of maturing NK cells. This educational function represents an additional challenge to finding the right dosing regimen or the appropriate combination partner.”
Innate Pharma is pursuing a broad and diversified pipeline of proprietary and partnered programs. Innate’s proprietary clinical product candidates IPH4102 and IPH5401 are progressing towards the next stages of clinical development as expected and an update is planned for early 2018 at an R&D event. Innate is also developing monalizumab, an antibody targeting NKG2A receptors on NK and CD8 T cells, which is partnered with AstraZeneca.
A conference call to the attention of institutional investors and sell-side analysts
will be held today at 6:30 pm CET.
Dial in numbers:
US: +18442860643 or International: +33172727403